B-Cell Lymphoma with Novartis Kymriah, Adult
Kymriah, developed by Novartis, is a type of immunotherapy for young adults (up to 25 years of age) with B-Cell Lymphoma. Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
3 Result(s)
Distance
10 Miles
1171 Miles
2434 Miles
Details
Similar Procedures
- B-Cell Lymphoma with Kite Yescarta, Adult
- Acute Lymphocytic Leukemia with Novartis Kymriah, Adult
- Large B-Cell Lymphoma with Juno Breyanzi
- Multiple Myeloma with Biotech Carvykti
- All & Mantle Cell Lymphoma with Kite Tecartus, Adult
- Acute Lymphocytic Leukemia with Novartis Kymriah, Pediatric
- Multiple Myeloma with Abecma
- Tumor-InfIltratIng Lymphocyte Therapy
- Multiple Myeloma with Biotech Carvykti
- Mantle Cell Lymphoma with Kite Tecartus, Adult
- B-Cell Lymphoma with Novartis Kymriah, Pediatric